Site search
2807 results for '' found
Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NCT04718389)
Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NCT04718389)
/
A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanc
A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanc
/
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter Randomized, controlled trial (NeoFOL-R) (ACTRN12624000005550)
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter Randomized, controlled trial (NeoFOL-R) (ACTRN12624000005550)
/
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to
/
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (VT3996-202) (NCT05011058)
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (VT3996-202) (NCT05011058)
/
Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA (NCT04949113)
Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA (NCT04949113)
/
NADOM trial – Neoadjuvant/ Adjuvant trial of Darovasertib in Ocular Melanoma (NCT05187884)
NADOM trial – Neoadjuvant/ Adjuvant trial of Darovasertib in Ocular Melanoma (NCT05187884)
/
More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures – MY-PROMPT-2 (TRU-MP2-22/AMaRC 22-02) (
More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures – MY-PROMPT-2 (TRU-MP2-22/AMaRC 22-02) (
/
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic
/
An Open-Label Extension Study to Investigate the Long-Term Safety, and Tolerability of Intracerebroventricular (ICV) Delivery of Valproate in Subjects with Focal Seizures, with Temporal Lobe Onse
An Open-Label Extension Study to Investigate the Long-Term Safety, and Tolerability of Intracerebroventricular (ICV) Delivery of Valproate in Subjects with Focal Seizures, with Temporal Lobe Onse
/